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Background: The influence of diabetes mellitus on myocardial ischemic preconditioning is not clearly defined.
Experimental studies are conflicting and human studies are scarce and inconclusive.
Objectives: Identify whether diabetes mellitus intervenes on ischemic preconditioning in symptomatic coronary
artery disease patients.
Methods: Symptomatic multivessel coronary artery disease patients with preserved systolic ventricular function and
a positive exercise test underwent two sequential exercise tests to demonstrate ischemic preconditioning. Ischemic
parameters were compared among patients with and without type 2 diabetes mellitus. Ischemic preconditioning
was considered present when the time to 1.0 mm ST deviation and rate pressure-product were greater in the second
of 2 exercise tests. Sequential exercise tests were analyzed by 2 independent cardiologists.
Results: Of the 2,140 consecutive coronary artery disease patients screened, 361 met inclusion criteria, and 174
patients (64.2 ± 7.6 years) completed the study protocol. Of these, 86 had the diagnosis of type 2 diabetes. Among
diabetic patients, 62 (72 %) manifested an improvement in ischemic parameters consistent with ischemic
preconditioning, whereas among nondiabetic patients, 60 (68 %) manifested ischemic preconditioning (p = 0.62).
The analysis of patients who demonstrated ischemic preconditioning showed similar improvement in the time to
1.0 mm ST deviation between diabetic and nondiabetic groups (79.4 ± 47.6 vs 65.5 ± 36.4 s, respectively, p = 0.12).
Regarding rate pressure-product, the improvement was greater in diabetic compared to nondiabetic patients
(3011 ± 2430 vs 2081 ± 2139 bpm x mmHg, respectively, p = 0.01).
Conclusions: In this study, diabetes mellitus was not associated with impairment in ischemic preconditioning in
symptomatic coronary artery disease patients. Furthermore, diabetic patients experienced an improvement in this
significant mechanism of myocardial protection.
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According to the World Health Organization, diabetes
mellitus (DM) is one of the most common chronic dis-
eases in the world, affecting 9.3 % of all adults older than
25 years [1]. Moreover, the prevalence of diabetes has been
substantially increasing during recent decades [2]. Diabetes
poses a high risk for the development of cardiovascular
diseases (CVD), because it heralds an accelerated process
of atherosclerosis and an increased risk for atherothrom-
botic complications [3]. CVDs are the leading causes of
death in diabetic patients [4] and the substantial rise in
diabetes prevalence will ultimately lead to an increase in
the burden of diabetes-related CVD in coming decades.
Among the cardiovascular diseases, ischemic heart
disease is the most frequent [5, 6] and is associated
with the highest morbidity and mortality in patients
with type 2 DM.
Despite the advances in the treatment of coronary artery
disease (CAD), morbidity and mortality are still high, es-
pecially in patients with type 2 DM [7]. Moreover, despite
the evolution in the treatment of hyperglycemia, patients
with both CAD and diabetes have worse clinical out-
comes, irrespective of the treatment applied [8].
Although DM alters the healthy functioning of arteries [9]
and blood compounds [10], some clinical studies sug-
gest that myocardial responses to ischemic insults may
be deficient in diabetic patients [11, 12], leading to
higher myocardial damage and risk of complications.
Thus, recent studies [13] have focused on the under-
standing of such myocardial responses, aiming at dis-
covering the mechanisms of myocardial protection to
achieve less aggression and a better prognosis.
A substantial effort has been put forth to investigate
any promising cardioprotective strategy to effectively re-
duce myocardial infarct size. And this matter is of particu-
lar importance to diabetic CAD patients [14]. By 1986, in
a landmark experimental study, Murry and colleagues
demonstrated that a short antecedent period of ischemia
could result in a great reduction in myocardial infarct size
[15]. For the first time, a method for reducing myocardial
cell death other than reperfusion had been discovered.
Since its discovery, this phenomenon, termed ischemic
preconditioning (IP) has been extensively studied.
Currently, IP is the intrinsic myocardial mechanism that
provides the greatest protection regarding the reduction
in myocardial ischemic damage. It has demonstrated a
75 % reduction in the infarcted area in animal models that
have undergone the preconditioning protocol [15].
IP is assumed as a mechanism of myocardial protection
in which brief episodes of sublethal myocardial ischemia
followed by reperfusion trigger multiple intracellular path-
ways that ultimately result in greater myocardial resistance
to a subsequent intense ischemic injury. Experimentally,
this phenomenon was demonstrated by the reduction inthe infarcted area by short episodes of ischemia prior to a
pronounced ischemic insult [15].
Although IP was initially thought to result from the
opening of collateral vessels and higher coronary flow [16],
some interesting studies have shown that the phenomenon
occurs irrespective of coronary flow changes [17, 18]. Such
studies also demonstrated that IP can be observed by se-
quential exercise tests (SETs), in which the improvement
in ischemic parameters in the second of 2 SETs were con-
firmed by invasive measurements of myocardial oxygen
consumption. Moreover, the clinical observation that pa-
tients with chronic ischemic heart disease frequently de-
scribe attenuation or even cessation of angina symptoms if
they rest and restart the exercise is termed “warm-up” or
“walk-through” angina. This phenomenon has been related
to IP and documented in studies using SETs [19, 20].
Following the demonstration of IP, the cellular mecha-
nisms underlying the phenomenon began to be investi-
gated. Although some cellular pathways have not been fully
elucidated, there is a growing understanding of some phe-
nomena and currently it is assumed that IP may be modu-
lated by external factors like age [21], diseases [22–24], as
well as some specific classes of medications [25–27].
Currently, the opening of K-ATP channels plays a fun-
damental role in the cellular cascades of IP [28]. It is also
assumed that medications that bind to this channel may
interfere with the IP mechanism. Thus, some classes of
medications like the oral hypoglycemic agents may also
block such channels in extrapancreatic sites, such as in
the heart. It has been shown by some authors that these
medications may cause the blockage of myocardial IP [29].
However, despite the fact that some oral hypoglycemic
agents may interfere with IP, it is still uncertain whether
the intrinsic, complex, intracellular alterations of diabetes
itself may affect the cellular mechanisms of this cardiopro-
tective phenomenon. Experimental studies aimed at study-
ing this question have shown conflicting results [30]. Some
of these studies have shown that diabetes does not inter-
fere with IP [31, 32], but others have shown negative influ-
ences [33, 34]. The great variability in these results is
especially due to differences in study protocols, most not-
ably the variability in animal models studied, in the proto-
cols to induce diabetes, the duration of the disease, as well
as the variability in myocardial injury protocols. On the
other hand, studies in humans are scarce and their results
have also been conflicting [12, 13, 35]. Thus, in this study,
we aimed at identifying IP in symptomatic multivessel
CAD patients and compared the results among patients
with and without type 2 DM.
Methods
Study design
This was a prospective study that included patients with
symptomatic CAD followed by the Medicine, Angioplasty,
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sign and protocol have been published elsewhere [36].
Briefly, patients were enrolled who had angina symptoms,
multivessel CAD, preserved left systolic ventricular func-
tion, and a recent, positive ischemic treadmill stress test.
All patients gave written informed consent. The diagnosis
of type 2 DM was based on American Diabetes Associ-
ation guidelines diagnostic criteria [37]. Multivessel CAD
was confirmed by the finding on cineangiocoronariogra-
phy of atherosclerotic stenosis of at least 70 % obstruction
in 2 or more coronary artery territories. The systolic ven-
tricular function was measured by transthoracic echocar-
diography and was considered preserved if ejection
fraction was ≥ 0.50. Treadmill exercise tests were con-
sidered positive for myocardial ischemia if a horizontal
or downsloping ST-segment deviation was ≥ 1.0 mm,
associated or not with thoracic discomfort. Exclusion
criteria were single-vessel CAD, left main CAD, impaired
systolic ventricular function (defined as an ejection frac-
tion < 0.50), recent and negative treadmill exercise test,
high-risk positive treadmill exercise test, limiting angina
symptoms, an acute coronary syndrome in the prior
3 months, electrocardiographic signs that could make
difficult the interpretation of ischemic changes (left
bundle-branch block, ST-segment deviation), arrhyth-
mias like atrial fibrillation or flutter, severe valvular dis-
ease, cardiomyopathies, or patient refusal to participate
in this study. The Ethics Committee of the HeartFig. 1 Study flow chart. Of the 2,140 initial CAD patients screened, 361 me
study protocol. The study population comprised 86 diabetic and 88 nondia
disease; CVA = cerebrovascular accident; ECG = electrocardiogram; EF = ejec
preconditioning; SET = sequential exercise test (s)Institute approved this study. All procedures were in
accordance with the terms of the Declaration of
Helsinki.
Patients
After cardiologic evaluation, all patients were instructed
to stop medications with cardiovascular properties 5 days
before SETs. Diabetic patients were also instructed to
stop antidiabetes medications 5 days before the tests.
Only nitrates were allowed until 12 h before the tests.
Patients were also recommended to not perform phys-
ical activities during the period without the use of medi-
cations and were under appropriate nutritional control.
A telephone contact was available 24 h a day in case of
questions or worsening symptoms. Before treadmill test
initiation, a medical team reassessed the symptoms to
ascertain clinical stability.
Sequential treadmill exercise tests
All patients underwent 2 SETs, symptom limited, with a
30-min interval between them. The modified Bruce
protocol was applied. Tests were conducted during the
same period each day, 1 h after lunchtime, on the same
treadmill, (MAT 2100 treadmill and a Fukuda Denshi
ML8000 Stress Test system (Fukuda Denshi; Bunkyo-ku,
Tokyo, Japan).
A 12-lead electrocardiogram, heart rate, and arterial
blood pressure were obtained with the patient in thet the inclusion criteria and were enrolled, and 174 completed the
betic patients. CAD = coronary artery disease; CKD = chronic kidney
tion fraction; ET = exercise test; DM = diabetes mellitus; IP = ischemic
Table 1 Main demographic, biochemical, and clinical
characteristics of the study population
Total N = 174 Diabetics (n = 86) Non-diabetics (n = 88) p Value
Age 64.1 ± 6.8 64.3 ± 8.6 0.84
Male n (%) 73 (84.9) 76 (86.3) 0.83
Hypertension 64 (80) 74 (84.1) 0.54
Smokers 7 (8.8) 7 (8.6)
Previous smokers 38 (48.1) 33 (40.7) 0.6
Non-smokers 34 (43.0) 41 (50.6)
Previous AMI 36 (46.1) 17 (22.7) 0.004
CABG 28 (34.6) 23 (26.1) 0.25
PCI 24 (30.4) 28 (32.2) 0.87
EF 0.61 ± 0.06 0.62 ± 0.06 0.2
Tri-vessel disease 38 (52) 43 (51.2) 1.0
Bi-vessel disease 35 (48) 41 (48.8) 1.0
LAD disease 63 (87.5) 74 (86.0) 1.0
Collateral circulation 34 (50.7) 38 (46.9) 0.64
Collateral grade 2/3 30 (88.2) 32 (84.2) 0.74
Weight (kg) 74.5 ± 11.0 73.2 ± 12.7 0.51
Height (m) 1.66 ± 8.1 1.66 ± 9.1 0.75
BMI 26.5 ± 2.8 26.4 ± 3.2 0.54
Fasting glycemia 143.5 ± 47.0 99.0 ± 9.4 0.0001
A1C 7.35 ± 1.61 5.63 ± 0.30 0.0001
BUN 41.9 ± 13.4 40.1 ± 9.4 0.32
Creatinine 1.04 ± 0.23 1.07 ± 0.20 0.37
Total cholesterol 156.5 ± 34.5 168.9 ± 36.3 0.02
LDL cholesterol 90.5 ± 27.4 102.0 ± 32.7 0.01
HDL cholesterol 38.0 ± 9.6 40.3 ± 9.0 0.12
Triglycerides 147.2 ± 88.3 132.6 ± 72.3 0.24
Data are expressed as means ± standard deviation or as absolute and
relative risks
AMI stands for acute myocardial infarction, CABG coronary artery bypass
surgery, PCI percutaneous coronary intervention, EF ejection fraction, LAD left
anterior descending, BMI body mass index, A1C glycosylated hemoglobin, BUN
blood urea nitrogen, LDL low-density lipoprotein, HDL high-density lipoprotein
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was also obtained at each 1.0-min interval during exercise,
at peak exercise, each minute up to 5 min during the re-
covery phase, at the onset of 1.0 mm ST-segment depres-
sion, during arrhythmias, and when it was clinically
relevant.
A computer-assisted electrocardiogram was monitored
during the exercise and recovery phases. The level of theTable 2 Classes of medications used by the two groups of diabetic
Aspirin / Clopidogrel Statins Beta-blockers AC
DM 93.2 % 93.2 % 89.8 % 78
Non-DM 96.5 % 96.5 % 86.2 % 78
DM stands for diabetic patients, Non-DM nondiabetic patients, ACEI angiotensin con
antidiabetic drugsST-segment deviation was based on visual assessment of
the 0.08 s after the J point by 2 independent cardiolo-
gists. In case of disagreement, a third cardiologist was
consulted, and the matter was resolved by consensus.
Only the horizontal or downsloping ST-segment devia-
tions were considered for the time to onset of 1.0-mm
ST-segment depression evaluation (T-1.0 mm). Criteria
for interrupting the exercise test were ST-segment de-
pression ≥ 3.0 mm, ST segment elevation ≥ 2.0 mm, max-
imum age-related heart rate, severe arterial hypotension
or hypertension, severe chest pain, physical exhaustion,
and sustained arrhythmias.
The following parameters were systematically mea-
sured: resting heart rate and arterial blood pressure,
heart rate and arterial blood pressure at peak exercise,
T-1.0 mm in seconds, rate pressure product (RPP) at the
onset of T-1.0 mm, and exercise duration in seconds.
The improvement in ischemic parameters (T-1.0 mm
and RPP) in the second exercise test compared to the
first one indicated the presence of IP. Both tests were
blinded for the cardiologist’s analysis.
Other parameters recorded during SETs were the total
exercise time, the occurrence and density of supraventricu-
lar and ventricular arrhythmias, and ST-segment deviation
morphology, during exercise and recovery phases. Both
arrhythmias and ST-segment morphology were graded ac-
cording to their density and severity.
According to the levels of fasting glycemia and glycosyl-
ated hemoglobin from baseline, patients were separated
into quartiles. For fasting glycemia, the quartiles were de-
fined as Quartile 1: < 90 mg/dL, Quartile 2: 90–100 mg/
dL, Quartile 3: 101–125 mg/dL, and Quartile 4: ≥ 126 mg/
dL. For glycosylated hemoglobin, the quartiles were de-
fined as Quartile 1: < 5.7 %, Quartile 2: 5.7–6.3 %, Quartile
3: 6.4–6.9 %, and Quartile 4: ≥ 7.0 %. The prevalence of
patients who expressed IP was compared among the
quartiles.
Sample size calculation
The sample size calculation has been previously pub-
lished elsewhere [36]. Briefly, it was determined by the
analysis of studies with similar methodologies that in-
cluded only diabetic patients [38] and studies that in-
cluded only nondiabetic patients [21]. By the differences
in T-1.0 mm in diabetic and nondiabetic patients, and
accounting for an expected loss of 30 % of patients who
do not demonstrate the IP phenomenon (estimatedand nondiabetic patients
EI / ARB Calcium blockers Diuretics OAD Insulins
.4 % 35.2 % 37.5 % 88.5 % 26.5 %
.2 % 36.8 % 34.5 % - -
verting enzyme inhibitors, ARB angiotensin receptor blockers, OAD oral
Fig. 2 Pie charts showing the number and percentage of diabetic and nondiabetic patients who demonstrated IP. IP = ischemic preconditioning
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tients with diabetes and 70 without diabetes should be in-
cluded to test the null hypothesis that the population
means were similar (power 0.9 and alpha error 0.05).
Statistical analysis
Continuous variables were compared using an unpaired
Student’s t test or Mann–Whitney test, when appropri-
ate. The Kolmogorov-Smirnov test was used to assess
the distribution of continuous variables. Discrete vari-
ables were compared using chi-squared test. Fisher’s test
was used when appropriate. Data are expressed as mean
± standard deviation or as absolute frequencies and per-
centages. The software SPSS, version 17.0, was used for
all statistical analyses. All tests were 2-sided, and a value
of p < 0.05 was considered significant.
Results
Of 2,140 patients with stable CAD followed at our insti-
tution, 361 met the inclusion criteria. Of those, 187 did
not complete the study protocol. The main reasons for
non-inclusion and exclusion are shown in Fig. 1. Thus, a
total of 174 patients completed the 2 SETs and had IP
assessed. The study population comprised 86 patients
with DM and 88 without this diagnosis (Fig. 1).
The main demographic, clinical and biochemical charac-
teristics of the 2 groups are presented in Table 1. DespiteTable 3 T-1.0 mm in exercise test 1 (ET1) and exercise test 2
(ET2) and the difference between the 2 tests (ET2-ET1) in
diabetic and nondiabetic patients who demonstrated IP (IP+) or
who did not demonstrate IP (IP-)
ET1 ET2 ET2-ET1 p Value*
DM 269.2 ± 117.8 320.9 ± 132.3 51.7 ± 63.2 0.15
Non-DM 275.6 ± 111.9 314.6 ± 126.2 39.0 ± 52.3
DM / IP+ 274.8 ± 102.8 354.3 ± 115.1 79.4 ± 47.6 0.12
Non-DM / IP+ 296.9 ± 107.7 362.4 ± 108.5 65.5 ± 36.4
DM / IP - 254.7 ± 151.6 234.7 ± 137.0 −20.0 ± 36.4 0.80
Non-DM / IP - 230.1 ± 108.7 212.4 ± 98.2 −17.7 ± 31.9
Data are expressed as means ± standard deviation. DM stands for diabetes
mellitus, IP + ischemic preconditioning present, IP - ischemic preconditioning
absent, ET, exercise test. * The p values are from the comparison of ET2-ET1
among diabetic and nondiabetic patientsthe higher prevalence of previous myocardial infarction in
the diabetic population and lipid profile (higher LDL-
cholesterol levels in nondiabetic patients), both groups had
homogeneous characteristics. The duration of diabetes was
11.5 ± 8.8 years (mean ± SD), with a median of 10 years
(interquartiles ranges of 6 and 15 years). Table 2 shows the
medications used in the two groups of patients.
Demonstration of IP
Among the 86 diabetic patients, 62 (72 %) had an im-
provement in T-1.0 mm consistent with IP. Among the
88 nondiabetic patients, 60 (68 %) had an ischemic im-
provement consistent with IP (Fig. 2, p = 0.62).
The T-1.0 mm results demonstrated that diabetic
patients who demonstrated IP had an improvement in
T-1.0 mm between the 2 SETs of 79.4 ± 47.6 s, whereas
nondiabetic patients who demonstrated IP had an im-
provement of 65.5 ± 36.4 s (Table 3, p = 0.12).
Regarding RPP, the group of diabetic patients who
demonstrated IP had an improvement of 3,011 ±
2,430 bpm x mmHg, whereas nondiabetic patients had
an improvement of 2,081 ± 2,139 bpm x mmHg (Table 4,
p = 0.01).
Table 5 shows the hemodynamic parameters heart rate
and blood pressure at baseline and peak exercise in the
4 groups of patients.Table 4 RPP in exercise test 1 (ET1) and exercise test 2 (ET2)
and the difference between the 2 tests (ET2-ET1) in diabetic and
nondiabetic patients who demonstrated IP (IP+) or who did not
demonstrate IP (IP-)
ET1 ET2 ET2-ET1 p
Value*
















−580 ± 2,250 0.43






Data are expressed as means ± standard deviation. DM stands for diabetes
mellitus, IP + ischemic preconditioning present, IP - ischemic preconditioning
absent, ET exercise test. * The p values are from the comparison of ET2-ET1
among diabetic and nondiabetic patients
Table 5 Hemodynamic parameters, heart rate and blood
pressure in the 4 groups of patients, diabetic and nondiabetic,
according to the demonstration of IP
Variables ET 1 ET 2 ET2-ET1
DM / IP + HR (baseline) 79.0 ± 15.1 86.3 ± 17.0 7.3 ± 11.0
HR (peak) 139.0 ± 15.1 142.1 ± 14.7 3.2 ± 5.6
BP (baseline) 156.5 ± 18.2 149.7 ± 19.3 −6.8 ± 12.6
BP (peak) 192.0 ± 25.0 191.8 ± 23.9 −0.16 ± 15.4
DM / IP - HR (baseline) 79.0 ± 14.7 84.4 ± 14.9 5.4 ± 8.0
HR (peak) 141.7 ± 14.3 143.0 ± 13.5 1.3 ± 7.4
BP (baseline) 153.3 ± 22.6 147.1 ± 19.7 −6.2 ± 14.7
BP (peak) 183.7 ± 23.2 180.6 ± 22.2 −3.12 ± 14.7
Non-DM / IP + HR (baseline) 78.0 ± 13.1 87.1 ± 13.9 9.1 ± 7.9
HR (peak) 139.6 ± 15.4 144.3 ± 14.7 4.7 ± 5.7
BP (baseline) 146.7 ± 20.6 138.7 ± 18.3 −8.0 ± 11.3
BP (peak) 193.5 ± 23.6 190.2 ± 24.5 −3.3 ± 12.4
Non-DM / IP - HR (baseline) 82.5 ± 12.9 87.1 ± 12.6 4.6 ± 7.1
HR (peak) 139.3 ± 12.4 139.6 ± 13.0 0.35 ± 5.2
BP (baseline) 158.6 ± 26.2 147.9 ± 26.1 −10.7 ± 14.6
BP (peak) 204.6 ± 25.3 194.8 ± 28.1 −8.9 ± 16.5
Data are expressed as means ± standard deviation. DM stands for diabetic
patients, Non-DM nondiabetic patients, IP + ischemic preconditioning present,
IP - ischemic preconditioning absent, ET exercise test
Table 6 Frequency of diabetes mellitus, and levels of fasting
glycemia and A1c in the study population according to the
expression of IP
IP + (n = 122) IP - (n = 52) p Value
DM n (%) 62 (50.8) 24 (46.1) 0.57
Fasting glycemia 121.3 ± 42.6 118.9 ± 34.1 0.72
A1c 6.63 ± 1.6 6.32 ± 1.2 0.25
Data are expressed as means ± standard deviation and as absolute and
relative frequencies
DM stands for diabetes mellitus, A1c glycosylated hemoglobin, IP + ischemic
preconditioning present, IP - ischemic preconditioning absent
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The improvement in the total exercise time comparing
the 2 SETs was similar between the groups of diabetic
and nondiabetic patients (20 ± 39 s versus 17 ± 36 s, re-
spectively, p = 0.60).
The improvement in the frequency and severity of ar-
rhythmias had similar results among diabetic and nondi-
abetic patients who experienced IP (50 % versus 63 % of
patients demonstrated improvement in arrhythmias, re-
spectively; p = 0.41).
The improvement in the ST-segment deviation morph-
ology was also similar among diabetic and nondiabetic
patients (38.5 % versus 48.3 %, respectively, p = 0.41).
Analysis of glycemic variables
When the total group of patients (n = 174) was stratified
according to the demonstration of IP, the frequency of
diabetic patients as well as the levels of fasting glycemia
and glycosylated hemoglobin were similar between the 2
groups, as shown in Table 6.
In addition, when we stratified patients by quartiles of
glycemia and glycosylated hemoglobin, there was no
statistical difference in terms of IP demonstration among
the different quartiles (Fig. 3).
Discussion
Considering that diabetes is an independent risk factor
for the occurrence of major cardiovascular events andmortality [5, 6], it is reasonable to consider that diabetes
might damage the protective mechanism of IP in CAD
patients, leading to worse outcomes. However, in this
study, the presence of type 2 DM did not have any dele-
terious effects on the myocardial protective mechanism
termed ischemic preconditioning.
In this context, our study showed that patients with
type 2 DM demonstrated IP in similar frequency and in-
tensity compared with nondiabetic patients and, interest-
ingly, our data indicated an improvement in ischemic
parameters associated with diabetes. The analyses of the
data showed a better ischemic response evaluated by
RPP in diabetic patients. Thus, this study adds clinical
information on some questions that have emerged from
contradictory experimental studies.
The improvement in myocardial oxygen consumption,
observed by the analysis of RPP, was more pronounced
in patients with compared to those without diabetes, in-
dicating better adaptation of the myocardium of diabetic
patients after an ischemic insult. Moreover, diabetic pa-
tients had an improvement in T-1.0 mm greater than
that in nondiabetic patients, although it did not reach
statistical significance. Analyzes of the total exercise time
also confirmed the main results of the study, as times
were similar among patients with and without DM.
Similarly, the ST-segment deviation morphology did not
differ among diabetic and nondiabetic patients.
Because myocardial ischemia is a frequent cause of ar-
rhythmias during treadmill stress tests, we also assessed
the occurrence and complexity of arrhythmias and their
improvement during SET. Thus, the improvement in the
occurrence of arrhythmias also confirmed the main find-
ings of the study, as the occurrence did not differ among
diabetic and nondiabetic patients.
Interestingly, analyzes of the percentage of patients
who demonstrated IP among different quartiles of fasting
glycemia and glycosylated hemoglobin showed similar
rates of IP demonstration. Thus, despite differences in gly-
cemic control, patients demonstrated IP in similar propor-
tions. This analyzes infer that the differences in the intensity
of glycemic control in our population did not prevent the
demonstration of this cardioprotective phenomenon.
Fig. 3 Graphs showing the percentage of patients who demonstrated ischemic preconditioning (IP+ in blue) and who did not demonstrate
ischemic preconditioning (IP - in red) stratified into quartiles of A1c (graph a) and Fasting Glycemia (graph b). IP = ischemic preconditioning;
Q = quartile (s). X axis represents the percentage of patients and Y axis the quartiles of A1c and Fasting Glycemia
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tion from this study is contrary to Lee’s et al. [11] and
Ishihara’s et al. [12], who have also studied IP in humans.
Lee et al. [11] studied diabetic and nondiabetic CAD
patients during percutaneous coronary interventions,
and evaluated the action of hypoglycemic agents on IP.
They enrolled patients with CAD and formal indication
for coronary intervention. Patients underwent consecutive
balloon coronary inflations. During the second sequential
balloon inflation, patients had less thoracic discomfort,
less myocardial lactate production, and lower ST-segment
deviation. Moreover, the authors observed that diabetic
patients treated with glimepiride had higher lactate pro-
duction compared to nondiabetic patients treated with gli-
mepiride. Despite this finding, an important limitation of
this study is that there was not a direct comparison of dia-
betic and nondiabetic patients who had no drug interfer-
ence in IP evaluation.
Ishihara et al. [12] studied patients hospitalized due to
an acute myocardial infarction and evaluated the effects
of preinfarct angina, on the release of cardiac markers of
necrosis, ventricular function, and in-hospital death and
compared the results among diabetic and nondiabetic
patients. The authors found that in the nondiabetic
population, patients with preinfarct angina had a lower
release of cardiac markers of necrosis, better recovery of
ventricular function, and lower in-hospital mortality,
compared to patients with no preinfarct angina. On the
other hand, when they analyzed diabetic patients, these
variables were not different among patients with and
without preinfarct angina. Thus, the authors inferred
that diabetes prevented the appearance of IP. Despite
their findings, Ishihara’s study has important limitations.
First, this was a retrospective study, which included a
small number of diabetic (n = 121) compared to nondia-
betic patients (n = 490). In addition, among the 121 dia-
betic patients, 53 were taking hypoglycemic medications.
Many studies have shown that some of these drugs mayblock IP [39], and it has been speculated that this inter-
ference with IP mechanisms may partially explain the
worse prognosis of diabetic patients hospitalized due to
an acute myocardial infarction [40].
On the other hand, other experimental studies that
evaluated “in vitro” human myocardial tissue [41, 42]
showed results that match those of the present study.
Ghosh et al. [41] studied human atrial appendages
from diabetic and nondiabetic patients after a severe is-
chemic insult. They evaluated the release of cardiac bio-
markers of necrosis and the percentage of tissue viability.
Among other findings, the authors found a similar inten-
sity in myocardial protection among diabetic and nondia-
betic patients.
Additionally, Cleveland et al. [42] evaluated the con-
tractile function of isolated right atrial trabeculae from
CAD patients, resected during coronary artery bypass
graft surgery. The authors observed the improvement in
the contractile strength after an ischemic insult. They
showed that the diabetic group that underwent the pre-
conditioning stimuli had similar improvement in con-
tractile function compared to the nondiabetic group.
Moreover, a small study conducted by Bilinska and
colleagues [35] with diabetic patients treated with glib-
enclamide, gliclazide, and diet compared the demonstra-
tion of IP in these groups with that in nondiabetic
patients. Besides the main findings of the study, which
were related to the effects of sulfonylureas in the warm-
up phenomenon, they showed that the group of diabetic
patients on diet (n = 15) had similar improvement in is-
chemic parameters compared to nondiabetic patients
(n = 17). Of note, this was a secondary result, and the
small sample size did not permit to make a definitive
conclusion.
Study limitations and strengths
This prospective study on IP in humans had a sample
size powered enough to compare IP demonstration in 2
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evaluated the possible interference of diabetes on a
myocardial protective mechanism. However, some reflec-
tion on the main findings is necessary. In this study, the
group of patients with diabetes was under strict control of
hyperglycemia, and this is observed by the controlled
levels of fasting glucose and glycosylated hemoglobin in
the group of diabetic patients. Assuming that hypergly-
cemia may interfere negatively with IP [43], it is possible
that the result of this study would be different in a popula-
tion under less strict hyperglycemic control.Clinical practice perspectives
Patients with symptomatic myocardial ischemia evolve
with diverse prognosis. In this context, the response of
the myocardium to an ischemic insult may probably play
an important role in prognosis. One mechanism that
may interfere with such a prognosis may be the presence
of a protective myocardial phenomenon, termed ische-
mic preconditioning. Because diabetes is an independent
risk factor for the occurrence of major cardiovascular
events, it is reasonable that it may compromise this car-
dioprotective mechanism, leading to worse outcomes.
Contrary to the initial expectation, the analysis of our
data revealed that diabetic patients showed this protective
phenomenon similarly to nondiabetic patients. Moreover,
diabetic patients had an improvement in hemodynamic
parameters. This study permits to demystify that diabetes
interferes with myocardial responses to ischemic insults.Conclusions
In this study, diabetes mellitus did not substantially
affect myocardial IP in symptomatic CAD patients. Fur-
thermore, diabetic patients experienced an improvement
in this significant mechanism of myocardial protection.Abbreviations
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